Island Pharmaceuticals Ltd (ASX:ILA) CEO Dr David Foster tells Proactive the company has been granted human research ethics approval to commence its ISLA-101 Single Ascending Dose study. The aim of the study is to ensure that administered doses can safely achieve blood concentrations of ISLA-101 that are predicted to be effective against the dengue virus. Recruitment and dosing will commence imminently, with the data read out expected in early 2024.
“This new patent adds to the growing intellectual property thicket that is being established around ISLA-101,” Foster said.
“This Australian patent, together with the equivalent patents granted in other key markets, underpin the investment we are making in bringing forward ISLA-101 as a potential new approach to combating the world’s growing problem with dengue fever and other mosquito-borne viral diseases.”
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
